产品名称
抗-BRCA2 (Ab-1) 小鼠mAb (2B), liquid, clone 2B, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
2B, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
dilution
(Immunoblotting (2 µg/mL)
Immunoprecipitation (2 µg))
isotype
IgG2b
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BRCA2(675)
Analysis Note
阳性对照
MCF7细胞
MCF7细胞
Application
免疫印迹法（2 µg/ml）
免疫沉淀（2 µg）
免疫沉淀（2 µg）
Disclaimer
毒性：标准处理（A）
General description
可识别表达野生型BRCA2基因的细胞中的~460 kDa BRCA2蛋白。根据美国专利号5,753,441和6,162,897的许可证销售。
抗BRCA2（Ab-1），小鼠单克隆，克隆2B，可识别表达野生型BRCA2基因的细胞中的~460 kDa BRCA2蛋白。它已被验证可用于蛋白质印迹和免疫沉淀。
通过用指定的免疫原免疫小鼠并将脾细胞与骨髓瘤细胞融合而产生的纯化小鼠单克隆抗体。可识别~460 kDa BRCA2蛋白。
Immunogen
人
由人BRCA2的氨基酸1651-1821与GST融合而成的重组蛋白
Legal Information
根据美国专利号5,837,492和6,124,104的许可证销售。
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Andres, J.L., et al. 1998.Oncogene16, 2229.
Chen, J., et al. 1998.Mol.Cell2, 317.
Chen, P.L., et al. 1998.Proc.Natl.Acad.Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998.Proc.Natl.Acad.Sci. USA95, 13869.
Connor, F., et al. 1997.Nat. Genet.17, 423.
Sharan, S.K., et al. 1997.Nature386, 804.
Ludwig, T., et al. 1997.Genes Dev.11, 1226.
Mizuta, R., et al. 1997.Proc.Natl.Acad.Sci. USA94, 6927.
Rajan, J.V., et al. 1997.Dev.Biol.184, 385.
Suzuki, A., et al. 1997.Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997.J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H.Skolnick.1996.Semin.Oncol.23, 1.
Goggins, M., et al. 1996.Cancer Res.56, 5360.
Stratton, M.R.1996.Hum.Mol.Genet.5, 1515.
Tavtigian, S.V., et al. 1996.Nat. Genet.12, 333.
Rajan, J.V., et al. 1996.Proc.Natl.Acad.Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock.1996.Oncogene13, 1639.
Vaughn, J.P., et al. 1996.Cancer Res.56, 4590.
Wooster, R., et al. 1995.Nature378, 789.
Chen, J., et al. 1998.Mol.Cell2, 317.
Chen, P.L., et al. 1998.Proc.Natl.Acad.Sci. USA95, 5287.
Marmorstein, L.Y., et al. 1998.Proc.Natl.Acad.Sci. USA95, 13869.
Connor, F., et al. 1997.Nat. Genet.17, 423.
Sharan, S.K., et al. 1997.Nature386, 804.
Ludwig, T., et al. 1997.Genes Dev.11, 1226.
Mizuta, R., et al. 1997.Proc.Natl.Acad.Sci. USA94, 6927.
Rajan, J.V., et al. 1997.Dev.Biol.184, 385.
Suzuki, A., et al. 1997.Genes Dev.11, 1242.
Wong, A.K.C., et al. 1997.J. Biol. Chem.272, 31941.
Cannon-Albright, L.A. and M.H.Skolnick.1996.Semin.Oncol.23, 1.
Goggins, M., et al. 1996.Cancer Res.56, 5360.
Stratton, M.R.1996.Hum.Mol.Genet.5, 1515.
Tavtigian, S.V., et al. 1996.Nat. Genet.12, 333.
Rajan, J.V., et al. 1996.Proc.Natl.Acad.Sci. USA93, 13078.
Spillman, M.A. and A.M. Bowcock.1996.Oncogene13, 1639.
Vaughn, J.P., et al. 1996.Cancer Res.56, 4590.
Wooster, R., et al. 1995.Nature378, 789.
在单个BRCA2等位基因中具有6174delT突变的CAPAN-1细胞系表达230 kDa的截短的BRCA2蛋白，该蛋白包含抗BRCA2表位并保留RAD51结合但失去了p53结合。全长BRCA2蛋白将在SDS-PAGE上与DNA PK的催化亚基共迁移，可以使用抗DNA PK（目录编号PC127）检测。在单个系统中，应对抗体进行滴定以获得最佳结果。
Packaging
请参考特定浓度批号的标签。
Physical form
溶于PBS。
Preparation Note
初次融化后，等分并冷冻（-20°C）。
未找到合适的产品？
试试我们的产品选型工具.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Nathalie van den Tempel et al.
Cancers, 11(1) (2019-01-18)
The DNA damage response (DDR) is a designation for a number of pathways that protects our DNA from various damaging agents. In normal cells, the DDR is extremely important for maintaining genome integrity, but in cancer cells these mechanisms counteract
Nathalie van den Tempel et al.
PloS one, 13(12), e0209101-e0209101 (2018-12-15)
Bladder cancer (urothelial carcinoma) is a common malignancy characterized by high recurrence rates and intense clinical follow-up, indicating the necessity for more effective therapies. Current treatment regimens include intra-vesical administration of mitomycin C (MMC) for non-muscle invasive disease and systemic
Reihaneh Zarrizi et al.
The Journal of clinical investigation, 130(8), 4069-4080 (2020-05-08)
Haploinsufficiency of factors governing genome stability underlies hereditary breast and ovarian cancer. One significant pathway that is disabled as a result is homologous recombination repair (HRR). With the aim of identifying new candidate genes, we examined early-onset breast cancer patients
null
Javier Garzón et al.
Cell reports, 27(9), 2558-2566 (2019-05-30)
RIF1 is a multifunctional protein implicated in controlling DNA replication and repair. Here, we show that human RIF1 protects nascent DNA from over-degradation at stalled replication forks. The major nuclease resecting nascent DNA in the absence of RIF1 is DNA2
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持